Low‐molecular‐weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST‐elevation myocardial infarction: a meta‐analysis
Open Access
- 20 July 2011
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 9 (10) , 1902-1915
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)European Heart Journal, 2010
- Experience with revascularization procedures does matter: low volume means worse outcomeEuropean Heart Journal, 2010
- Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa InhibitorJournal of Korean Medical Science, 2010
- Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarctionThrombosis and Haemostasis, 2008
- Enoxaparin versus Unfractionated Heparin in Elective Percutaneous Coronary InterventionNew England Journal of Medicine, 2006
- Comparison of Enoxaparin Versus Heparin During Elective Percutaneous Coronary Intervention Performed With Either Eptifibatide or Tirofiban (The ACTION Trial)The American Journal of Cardiology, 2005
- Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcomeEuropean Heart Journal, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin in the Prehospital SettingCirculation, 2003
- Analysis of data from multiclinic trialsControlled Clinical Trials, 1986